Latest Articles
Endometrial Cancer: Toxicity Management and Treatment Persistence with Lenvatinib-Pembrolizumab - OncLive
Endometrial Cancer: Toxicity Management and Treatment Persistence with Lenvatinib-Pembrolizumab OncLive
Published: Dec. 26, 2025, 1:19 p.m.
Dosimetry, Toxicity, and Outcomes of Medically Inoperable Endometrial Cancer Treated With Definitive External Beam Radiation Therapy and Brachytherapy - Cureus
Dosimetry, Toxicity, and Outcomes of Medically Inoperable Endometrial Cancer Treated With Definitive External Beam Radiation Therapy and Brachytherapy Cureus
Published: Aug. 13, 2025, 1:15 p.m.
Toxicity and Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer: A Real-World Retrospective Analysis - Frontiers
Toxicity and Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer: A Real-World Retrospective Analysis Frontiers
Published: Aug. 7, 2025, 7:56 a.m.
Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC - CancerNetwork
Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC CancerNetwork
Published: June 17, 2025, 6:09 p.m.
Link copied to clipboard!